Abstract P3-01-04: A real-world evidence study of everolimus plus endocrine therapy beyond CDK4/6 inhibitors for HR+/HER2- advanced breast cancerRodrigo Sánchez-Bayona, Eva Ciruelos, Ana Sánchez et al.|Cancer Research|2023Cited by 1
Abstract P5-02-44: Efficacy analysis of CDK4/6 inhibitors in combination with endocrine therapy treatment in HR+/HER2- breast cancer according to PAM50 intrinsic subtype: primary results of SOLTI-1801_CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Tomás Pascual et al.|Cancer Research|2023Cited by 0